New combo therapy aims to stop rare bone cancer from spreading
NCT ID NCT07115667
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether combining radiation with a bispecific antibody called CM336 can safely treat solitary bone plasmacytoma, a rare plasma cell tumor that often turns into multiple myeloma. The study will enroll 21 adults with mild bone marrow involvement. Researchers will monitor side effects, especially immune overreactions, and track how long participants stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCMA/CD3 bispecific antibody (CM336) combined with radiation therapy
- What this could lead to
- If successful, this combination could offer a new treatment option that delays or prevents progression to multiple myeloma for people with solitary bone plasmacytoma.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The bispecific antibody can cause serious side effects like cytokine release syndrome (CRS) and nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer aims to reveal hidden myeloma spots
- New drug combo aims to shrink plasma cell tumors
- Simple blood test could catch myeloma years earlier in High-Risk groups
- Mayo clinic launches gut bacteria study for rare plasma cell disorders
- Power drill vs. needle: which makes bone marrow biopsy less painful?